Clinical efficacy of Camrelizumab combined with first-line chemotherapy in extensive-stage small-cell lung cancer.

As far as PD-1 inhibitors are concerned, the OS of KEYNOTE-604 did not reach statistical significance, which may be related to the more severe disease of the enrolled population.

also in 111,027 other papers